BioAMPS International, LLC had been an early stage life science company focused on the development of proprietary antimicrobial peptide (AMPS) therapeutics for the treatment of systemic infectious diseases with the goal of commercializing the first structurally-guided antimicrobial peptide solution to the global problem of antibiotic resistance by gram-negative and gram-positive bacterial organisms. Principals of the firm had been looking to develop - and eventually market - novel peptide-based antimicrobial agents. In addition to developing purification protocols (up to 1 gram at present) for promising lead agents, Not clear if the firm is stili operational (03/2019)
